What it sells
Using protein coupling to build new therapies
Business model breakdown
Buyer: who owns the budget?
UnverifiedBiopharma partners and investors licensing or co-developing ADC assets (inferred; therapeutics developer, no sales buyer).
Workflow: what inputs become what output?
CysTyr conjugation platform attaches multiple payload types to one antibody via a cystine-tyrosine C-Y Bond to make Multi-Payload Conjugates for solid tumors.
Economics: what it saves and how it charges
UnverifiedPreclinical biotech; value comes from pipeline and partnering/licensing, no product revenue stated.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Summer 2021 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.